Humulin nph sus. for subcutaneous injection cartridges 100 units/ml 3 ml №5

Dosage form

Suspension for injection

Composition

1 ml contains insulin isophane human biosynthetic suspension 100 IU

Packing

5 cartridges of 3 ml.

Mechanism of action

DNA recombinant human insulin. Humulin NPH is an insulin medication of average duration of action.
The main effect of the drug is the regulation of glucose metabolism. In addition, it has an anabolic effect. In muscle and other tissues (with the exception of the brain), insulin causes rapid intracellular transport of glucose and amino acids, accelerates protein anabolism. Insulin contributes to the conversion of glucose to glycogen in the liver, inhibits gluconeogenesis and stimulates the conversion of excess glucose to fat.

Indications and usage

- diabetes in the presence of indications for insulin therapy;
- newly diagnosed diabetes;
- pregnancy in type 2 diabetes mellitus (non-insulin-dependent).

Contraindications

- hypoglycemia;
- hypersensitivity to insulin or to one of the components of the drug Humulin NPH.

Pregnancy and Breastfeeding

In pregnancy, it is especially important to maintain good glycemic control in patients with diabetes. During pregnancy, the need for insulin usually decreases in the first trimester and increases in the second and third trimesters.
Patients with diabetes are advised to inform the doctor about the onset or planning of pregnancy.
In patients with diabetes mellitus during lactation (breastfeeding), it may be necessary to adjust the dose of insulin, diet, or both.
In studies of genetic toxicity in the in vitro and in vivo series, human insulin did not have a mutagenic effect.

Dosage and administration

Dose Humulin NPH set by the doctor individually, depending on the level of glycemia.
The drug should be administered s / c, possibly in / m introduction. In / in the introduction of Humulin NPH contraindicated!
P / to the drug is administered to the shoulder, thigh, buttocks or abdomen. The injection site must be alternated so that the same place is used no more than about 1 time / month.
When s / c administration, care must be taken to avoid falling into a blood vessel. After the injection should not massage the injection site. Patients should be trained in the proper use of insulin injection devices.

Adverse reactions

Side effect associated with the main action of the drug: hypoglycemia.
Severe hypoglycemia can lead to loss of consciousness and (in exceptional cases) death.
Allergic reactions: local allergic reactions are possible - hyperemia, swelling or itching at the injection site (usually stopped for a period ranging from several days to several weeks); systemic allergic reactions (occur less frequently, but are more serious) - generalized itching, difficulty breathing, shortness of breath, decreased blood pressure, increased heart rate, increased sweating. Severe cases of systemic allergic reactions can be life threatening.
Other: the likelihood of developing lipodystrophy is minimal.

Special notes

The transfer of a patient to another type of insulin or to an insulin preparation with a different trade name should be carried out under strict medical supervision. Changes in insulin activity, its type (for example, Regular, M3), species (porcine, human insulin, human insulin analogue), or production method (DNA-recombinant insulin or insulin of animal origin) may lead to the need for dose adjustment.
The need for dose adjustment may be required already at the first injection of human insulin after insulin of animal origin, or gradually over several weeks or months after transfer.
The need for insulin may decrease with insufficient adrenal, pituitary, or thyroid function, or with renal or hepatic failure.
In some diseases or emotional stress, the need for insulin may increase.
Dose adjustment may also be required with increasing physical exertion or with a change in the normal diet.
Symptoms are precursors of hypoglycemia in the presence of the introduction of human insulin in some patients may be less pronounced or different from those observed in the presence of insulin of animal origin. When the blood glucose level normalizes, for example, as a result of intensive insulin therapy, all or some of the symptoms, precursors of hypoglycemia, can disappear, about which patients should be informed.
Symptoms, precursors of hypoglycemia may change or be less pronounced with long-term diabetes mellitus, diabetic neuropathy, or with simultaneous use of beta-blockers.
In some cases, local allergic reactions can be caused by causes not related to the action of the drug, such as skin irritation with a cleansing agent or improper injection.
In rare cases, the development of systemic allergic reactions require immediate treatment. Sometimes it may be necessary to change insulin or desensitization.
Influence on ability to drive motor transport and control mechanisms
During hypoglycemia, the patient may deteriorate the ability to concentrate and decrease the speed of psychomotor reactions. This can be dangerous in situations in which these abilities are especially needed (driving a car orcontrol mechanisms). Patients should be advised to take precautions to avoid hypoglycemia while driving. This is especially important for patients with mild or absent symptoms that are precursors of hypoglycemia or with the frequent development of hypoglycemia. In such cases, the doctor must assess the feasibility of driving the car by the patient.

Hypoglycemic effect of Humulin NPH reduces oral contraceptives, corticosteroids, thyroid hormone drugs, thiazide diuretics, diazoxide, tricyclic antidepressants.
The hypoglycemic effect of Humulin NPH is enhanced by oral hypoglycemic drugs, salicylates (for example, acetylsalicylic acid), sulfonamides, MAO inhibitors, beta-blockers, ethanol and ethanol-containing drugs.
Beta-blockers, clonidine, reserpine can mask the manifestation of symptoms of hypoglycemia.
Pharmaceutical Interaction
The effects of mixing human insulin with animal insulin or human insulin produced by other manufacturers have not been studied.

Overdosage

Symptoms: hypoglycemia, accompanied by lethargy, increased sweating, tachycardia, pallor of the skin, headache, tremor, vomiting, confusion.
Under certain conditions, for example, with long duration or with intensive control of diabetes mellitus, the symptoms of precursors of hypoglycemia may change.
Treatment: Light states of hypoglycemia can usually be stopped by ingestion of glucose (dextrose) or sugar. You may need a dose adjustment of insulin, diet, or physical activity.
Correction of moderate hypoglycemia can be performed using i / m or s / c administration of glucagon, followed by ingestion of carbohydrates.
Severe conditions of hypoglycemia, accompanied by coma, convulsions or neurological disorders, arrest intramuscular or subcutaneous injection of glucagon or intravenous administration of concentrated glucose solution (dextrose). After the recovery of consciousness, the patient must be given food rich in carbohydrates in order to avoid the recurrence of hypoglycemia.

Storage conditions

The drug should be stored in a refrigerator at a temperature of 2 ° to 8 ° C, prevent freezing, protect from direct exposure to light.

2 years.